Web Map For Collection 中文 English
Home About us Organization Principal Investigators Research Education& Training Academic activities Facilities Careers Downloads Contact us
Location:Home - Principal Investigators
Xiaojun HUANG

Xiaojun HUANG


Email: xjhrm(at)medmail(dot)com(dot)cn;



Research Area:

Prof. Huang focuses on the clinical and experimental fields of hematology and hematopoietic stem cell transplantation (HSCT). By combining the breakthroughs of mechanism research and new biomarkers for precise diagnosis, Prof. Huang aims to establish novel therapeutic strategies for critical hematological problems. The current studies follow the pattern as“ Clinical Models—In vitro or vivo Experiments—Improve Therapeutic Strategies”, which mainly include:

(1)Immunomodulatory strategies to overcome leukemia relapse after HSCT;

(2)Haploidentical HSCT system and immune tolerance;

(3)Biomarkers of hematologic malignancies and HSCT related complications.


Selected Publications:


1.      Zhu HH, Qin YZ, Huang XJ*. Resistance to arsenic therapy in acute promyelocytic leukemia. N Engl J Med.2014;370(19):1864-1866.
2.      Wang Y, Wu DP, Liu QF, Qin YZ, Wang JB, Xu LP, Liu YR, Zhu HH, Chen J, Dai M, Huang XJ*. RUNX1/RUNX1T1-based MRD-monitoring early after allogeneic transplantation rather than c-KIT mutations in adult t(8;21) AML allows further risk stratification. Blood. 2014. pii: blood-2014-03-563403. [Epub]
3.      Wang Y, Chang YJ, Xu LP, Liu KY, Liu DH, Zhang XH, Chen H, Han W, Chen YH, Wang FR, Wang JZ, Chen Y, Yan CH, Huo MR, Li D, Huang XJ*. Who is the best donor for a related HLA haplotype-mismatched transplant? Blood.2014;124(6):843-850.
4.      Zhu HH, Zhang XH, Qin YZ, Liu DH, Jiang H, Chen H, Jiang Q, Xu LP, Lu J, Han W, Bao L, Wang Y, Chen YH, Wang JZ, Wang FR, Lai YY, Chai JY, Wang LR, Liu YR, Liu KY, Jiang B, Huang XJ*. MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. Blood.2013;121(20):4056-4062.
5.      Huang XJ*, Zhu HH, Chang YJ, Xu LP, Liu DH, Zhang XH, Jiang B, Jiang Q, Jiang H, Chen YH, Chen H, Han W, Liu KY, Wang Y. The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission.Blood. 2012;119(23):5584-5590.
6.      Yan CH, Liu DH, Liu KY, Xu LP, Liu YR, Chen H, Han W, Wang Y, Qin YZ, Huang XJ*. Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood. 2012;119(14):3256-3262.
7.      Jiang Q, Xu LP, Liu DH, Liu KY, Chen SS, Jiang B, Jiang H, Chen H, Chen YH, Han W, Zhang XH, Wang Y, Qin YZ, Liu YR, Lai YY, Huang XJ*. Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase. Blood. 2011;117(11):3032-3040.
8.      Xiao-Jun H*, Lan-Ping X, Kai-Yan L, Dai-Hong L, Yu W, Huan C, Yu-Hong C, Wei H, Jing-Zhi W, Yao C, Xiao-Hui Z, Hong-Xia S, Feng-Rong W, Fei-Fei T. Partially matched related donor transplantation can achieve outcomes comparable with unrelated donor transplantation for patients with hematologic malignancies. Clin Cancer Res. 2009;15(14):4777-4783.
9.      Zhao XY, Lv M, Xu LL, Qian X, Huang XJ*. Donor Th17 cells and IL-21 may contribute to the development of chronic graft-versus-host disease after allogeneic transplantation. Eur J Immunol. 2013;43(3):838-850.
10.   Zhao XY, Chang YJ, Xu LP, Zhang XH, Liu KY, Li D, Huang XJ*. HLA and KIR genotyping correlates with relapse after T-cell-replete haploidentical transplantation in chronic myeloid leukaemia patients. Br J Cancer. 2014. doi: 10.1038/bjc.2014.423. [Epub]



All right reserved Center For Life Sciences